focus -WSS

focus

author：comprehensive 2025-10-02 21:35:23 - browse：3

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： California wildfire smoke linked to 52,000 early deaths, study says

WSS

Report captures long Covid’s disabling effects and policy challenges

New report analyzes digital physical therapy solutions' effectiveness

WHO may add ‘noma' to its list of neglected tropical diseases

Physician subsidies by hospitals soar in wake of No Surprises Act

Telehealth options flood the market as retailers push virtual care

CDC recommends rationing of RSV shot due to shortages

explore

focus

leisure time

Medicare details structure of new drug price negotiation program

Cheap, fast test for Zika and dengue could cost just $1

Novavax promises a turnaround & Lilly roils the obesity market

How faith leaders like me can help address America's obesity epidemic

How to save PrEP access — and even expand it

STAT Virtual Event: ASCO Recap, Live!

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How faith leaders like me can help address America's obesity epidemic

Novavax promises a turnaround & Lilly roils the obesity market

Paying for Covid pills will soon shift to insurers

leisure time

Meta's Zuckerberg and Chan on track to put $50 billion into science

Meta's Zuckerberg and Chan on track to put $50 billion into science

STAT Virtual Event: ASCO Recap, Live!

Cheap, fast test for Zika and dengue could cost just $1

Statins may not be needed by millions of people, study suggests

My daughter's legacy lives on through her writing, phage therapy

focus

hotspot

focus

entertainment